Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1988 Aug;94(4):1043–1050. doi: 10.1111/j.1476-5381.1988.tb11620.x

Psoriatic skin lesions contain a novel lipid neutrophil chemokinetic compound which is distinct from known chemoattractant eicosanoids.

R D Camp 1, F M Cunningham 1, N J Fincham 1, M W Greaves 1, A Kobza Black 1, A I Mallet 1, P M Woollard 1
PMCID: PMC1854099  PMID: 3061542

Abstract

1. Lipid extracts of scale from the lesions of the skin disease psoriasis were purified by high performance liquid chromatography (h.p.l.c.). Assay of fractions by an agarose microdroplet method showed the presence of a novel neutrophil chemokinetic compound which possessed the chromatographic properties of a monohydroxy fatty acid, yet was distinct from the chemoattractant eicosanoid, 12-hydroxyeicosatetraenoic acid, previously isolated in psoriasis. 2. The novel, material, termed compound X, was also detected in fractions collected on h.p.l.c. of extracts of chamber fluid samples obtained from abraded psoriatic lesions, but was not detectable in samples from clinically normal skin. 3. Comparison of the straight and reversed phase h.p.l.c. retention times of compound X with those of a range of standard monohydroxy fatty acids, together with further analysis by gas chromatography-mass spectrometry and assay of selected standards for neutrophil chemokinetic activity, failed to reveal the structural identity of compound X. 4. The finding of a further compound in psoriatic lesions, which stimulates neutrophil movement, highlights the complexity of inflammatory mediator production in this disease.

Full text

PDF
1043

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barr R. M., Wong E., Mallet A. I., Olins L. A., Greaves M. W. The analysis of arachidonic acid metabolites in normal, uninvolved and lesional psoriatic skin. Prostaglandins. 1984 Jul;28(1):57–65. doi: 10.1016/0090-6980(84)90113-8. [DOI] [PubMed] [Google Scholar]
  2. Brain S. D., Camp R. D., Cunningham F. M., Dowd P. M., Greaves M. W., Black A. K. Leukotriene B4-like material in scale of psoriatic skin lesions. Br J Pharmacol. 1984 Sep;83(1):313–317. doi: 10.1111/j.1476-5381.1984.tb10148.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brain S., Camp R., Dowd P., Black A. K., Greaves M. The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis. J Invest Dermatol. 1984 Jul;83(1):70–73. doi: 10.1111/1523-1747.ep12261712. [DOI] [PubMed] [Google Scholar]
  4. Camp R. D., Fincham N. J., Cunningham F. M., Greaves M. W., Morris J., Chu A. Psoriatic skin lesions contain biologically active amounts of an interleukin 1-like compound. J Immunol. 1986 Dec 1;137(11):3469–3474. [PubMed] [Google Scholar]
  5. Camp R. D., Mallet A. I., Woollard P. M., Brain S. D., Black A. K., Greaves M. W. The identification of hydroxy fatty acids in psoriatic skin. Prostaglandins. 1983 Sep;26(3):431–447. doi: 10.1016/0090-6980(83)90178-8. [DOI] [PubMed] [Google Scholar]
  6. Cunningham F. M., Woollard P. M. 12(R)-hydroxy-5,8,10,14-eicosatetraenoic acid is a chemoattractant for human polymorphonuclear leucocytes in vitro. Prostaglandins. 1987 Jul;34(1):71–78. doi: 10.1016/0090-6980(87)90264-4. [DOI] [PubMed] [Google Scholar]
  7. Cunningham F. M., Woollard P. M., Camp R. D. Proinflammatory properties of unsaturated fatty acids and their monohydroxy metabolites. Prostaglandins. 1985 Sep;30(3):497–509. doi: 10.1016/0090-6980(85)90122-4. [DOI] [PubMed] [Google Scholar]
  8. Hammarström S., Hamberg M., Samuelsson B., Duell E. A., Stawiski M., Voorhees J. J. Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E2, and prostaglandin F2alpha in epidermis of psoriasis. Proc Natl Acad Sci U S A. 1975 Dec;72(12):5130–5134. doi: 10.1073/pnas.72.12.5130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Mallet A. I., Cunningham F. M., Daniel R. Rapid isocratic high-performance liquid chromatographic purification of platelet activating factor (PAF) and lyso-PAF from human skin. J Chromatogr. 1984 Jul 13;309(1):160–164. doi: 10.1016/0378-4347(84)80018-3. [DOI] [PubMed] [Google Scholar]
  10. Mallet A. I., Cunningham F. M. Structural identification of platelet activating factor in psoriatic scale. Biochem Biophys Res Commun. 1985 Jan 16;126(1):192–198. doi: 10.1016/0006-291x(85)90590-x. [DOI] [PubMed] [Google Scholar]
  11. Ragaz A., Ackerman A. B. Evolution, maturation, and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings. Am J Dermatopathol. 1979 Fall;1(3):199–214. doi: 10.1097/00000372-197900130-00002. [DOI] [PubMed] [Google Scholar]
  12. Schröder J. M., Christophers E. Identification of C5ades arg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales. J Invest Dermatol. 1986 Jul;87(1):53–58. doi: 10.1111/1523-1747.ep12523566. [DOI] [PubMed] [Google Scholar]
  13. Smith M. J., Walker J. R. The effects of some antirheumatic drugs on an in vitro model of human polymorphonuclear leucocyte chemokinesis. Br J Pharmacol. 1980 Jul;69(3):473–478. doi: 10.1111/j.1476-5381.1980.tb07037.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Takematsu H., Ohkohchi K., Tagami H. Demonstration of anaphylatoxins C3a, C4a and C5a in the scales of psoriasis and inflammatory pustular dermatoses. Br J Dermatol. 1986 Jan;114(1):1–6. doi: 10.1111/j.1365-2133.1986.tb02773.x. [DOI] [PubMed] [Google Scholar]
  15. Woollard P. M. Stereochemical difference between 12-hydroxy-5,8,10,14-eicosatetraenoic acid in platelets and psoriatic lesions. Biochem Biophys Res Commun. 1986 Apr 14;136(1):169–176. doi: 10.1016/0006-291x(86)90891-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES